miR-29a and miR-181 negatively regulate the expression of TCL1, an oncogene whose high expression is found in aggressive forms of CLL [44], and also downregulated BCL-2 [45,46]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.